Cyteir Therapeutics, Inc. (CYT) News
Filter CYT News Items
CYT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CYT News From Around the Web
Below are the latest news stories about CYTEIR THERAPEUTICS INC that investors may wish to consider to help them evaluate CYT as an investment opportunity.
Cyteir Therapeutics Promotes David Gaiero to Chief Financial OfficerLEXINGTON, Mass., February 06, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department, to oversee the company’s overall financial operations, and to help drive the long-term business and financial strategy of Cyteir, reporting directly to the President & CEO. |
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash RunwayLEXINGTON, Mass., January 19, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. The prioritization follows encouraging preliminary clinical activity in a small number of patients observed in the Phase 1 dose escalation cohort with CYT-0851 in combination with capecitabine in advan |
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational HighlightsLEXINGTON, Mass., November 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights. |
Great news for Cyteir Therapeutics, Inc. (NASDAQ:CYT): Insiders acquired stock in large numbers last yearWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR SymposiumLEXINGTON, Mass., October 12, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targ |
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceLEXINGTON, Mass., August 31, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. |
We're Keeping An Eye On Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational HighlightsLEXINGTON, Mass., August 08, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent operational highlights. |
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceLEXINGTON, Mass., August 01, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022. |
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic MalignanciesLEXINGTON, Mass., June 05, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today presented results from a Phase 1 dose escalation monotherapy trial with CYT-0851 in a poster titled "Phase 1 Results of CYT-0851 in Patients with Advanced Solid and Hematologic Cancers" (Abstract: 3084, Poster: 76) at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicag |